WALDENSTRÖM MACROGLOBULINEMIA (WM)
Clinical trials for WALDENSTRÖM MACROGLOBULINEMIA (WM) explained in plain language.
Never miss a new study
Get alerted when new WALDENSTRÖM MACROGLOBULINEMIA (WM) trials appear
Sign up with your email to follow new studies for WALDENSTRÖM MACROGLOBULINEMIA (WM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for rare blood cancer
Disease control OngoingThis phase 2 study tests acalabrutinib, a targeted drug, in 107 people with Waldenström macroglobulinemia, a rare blood cancer. The goal is to see how well the drug shrinks tumors and controls the disease. Participants either had prior treatment or are new to therapy and cannot t…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA (WM)
Phase: PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Is 'Watch and Wait' really 'Worry and Wait'? new study investigates
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how the 'watch and wait' approach affects the quality of life of people with slow-growing lymphomas like CLL and follicular lymphoma. Researchers will ask 250 Korean patients to fill out questionnaires about their well-being and anxiety. The goal is to underst…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA (WM)
Sponsor: Seoul National University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC